INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory airway condition associated with episodes of acute deterioration termed exacerbations (1) . Exacerbations are amongst the commonest causes of medical admission to hospital (2) and the rate at which they occur appears to reflect an independent susceptibility phenotype (3). They are also important events in the natural history of COPD that drive lung function decline (4, 5) , increase risk of cardiovascular events (6) and are responsible for much of the morbidity (7) and mortality (8) associated with this highly prevalent condition.
COPD exacerbations are characterized by a worsening of respiratory symptoms from the usual stable state, especially dyspnea, increased sputum volume and purulence. Changes in exacerbation symptoms relate to exacerbation recovery time (9) , which is an index of exacerbation severity. In addition to exacerbation length, exacerbation severity influences acute treatment (9) , drives hospital admission and also mortality (8) .
Patient diary cards are direct measures of exacerbation symptoms that provide accurate information regarding the commencement and resolution of exacerbations (9) . They can detect exacerbations that are both reported and unreported to health care professionals thus allowing accurate determination of exacerbation frequency (7) . However, currently there is no standardized, objective method for assessing symptom severity at exacerbation that has been universally accepted and available for use in both routine clinical practice and clinical trials. The COPD Assessment Test TM (CAT) is a validated 8-item questionnaire designed to assess and quantify the impact of COPD symptoms on patient health status ( Figure 1 ). It has excellent measurement properties (10) and is short and simple for patients to complete, providing a score out of 40 to indicate disease impact, without the need for complex calculation. Initial studies have shown that the CAT correlates closely with health-related quality of life as measured by the St. George's Respiratory Questionnaire (SGRQ) when patients are stable (10) , and is responsive to pulmonary rehabilitation (11) .
We hypothesized that elevated CAT scores at COPD exacerbation relate to exacerbation severity as measured by exacerbation length, lung function impairment and systemic inflammation. Furthermore, we hypothesized that CAT scores can be used to model recovery.
Therefore, well characterized patients were prospectively assessed using the CAT in the baseline stable state, at exacerbation presentation and thereafter for five weeks during the recovery period.
METHODS

Patient recruitment
This study involved 161 COPD patients enrolled in the London COPD cohort between 1st Ethical approval for the study was granted from the Royal Free Hospital research ethics committee and all patients gave written informed consent. Permission to use the CAT questionnaire was obtained from GlaxoSmithKline. The recruitment and monitoring of these patients has been previously described and the cohort has been the subject of previous publications (7, 9, (14) (15) (16) ), but the current study is entirely novel and has not been reported before.
Monitoring and Definition of Exacerbations
Patients were asked to record daily peak expiratory flow rate (PEFR) measured with a miniWright meter (Clement-Clark International, Harlow, UK), hours spent outside the home and any increase in respiratory symptoms on diary cards. An exacerbation was defined as an increase for two consecutive days in respiratory symptoms, with at least one major symptom (dyspnea, sputum purulence or sputum volume) plus either another major or a minor symptom (wheeze, cold, sore throat, and cough), the first of which was defined as the day of onset of the exacerbation. and the number of exacerbations remembered by the patient over the same 1 year period (17) and has shown that exacerbation frequency represents a stable patient phenotype (3).
Exacerbation Assessment
Exacerbations were treated according to the prevailing guidelines and clinical judgment with increased inhaled therapy, antibiotics and/or oral steroids. Neither the magnitude of exacerbation CAT score nor the diary card symptom score played any role in treatment decisions. When patients attended for an exacerbation, venous blood samples were taken and spirometry performed prior to commencing exacerbation treatment. Serum C-reactive protein (CRP) was measured using Modular Analytics E 170 Module (Roche, Burgess Hill, UK) and plasma fibrinogen using the Clauss method (IL ACL Top Coagulation Analyzer, Lexington, MA, USA).
CAT administration
Patients completed the CAT at least once under supervision in clinic and then at home, based used to analyze the relationship between inflammatory markers during exacerbation and CAT score as allowance could be made for repeated measures on the same patient.
Statistical analysis
RESULTS
Patient Characteristics
161 COPD patients completed at least one CAT questionnaire when stable (exacerbation free). Their baseline characteristics are reported in Table 1 alongside 75 patients who were assessed using the CAT at exacerbation and the 52 of these who completed the CAT questionnaire daily during exacerbation recovery. The patients had moderate to severe disease with a mean FEV 1 % predicted of 50.3% (range 14.0-79.7%). Patients in whom CAT was assessed at exacerbation had significantly higher exacerbation frequencies (p<0.001) but differed in no other respect.
Patients completed the CAT successfully when stable and when acutely unwell during an exacerbation. In total, 6404 out of 6514 questionnaires (98.3%) were completed fully. There was no significant difference in the percentages fully completed at baseline, 3496 of 3561 (98.2%) compared to those at exacerbation onset and during recovery, 2908 of 2953 (98.5%; p=0.35).
Use of CAT at Baseline
Baseline CAT and exacerbation frequency
The 161 patients had a mean baseline CAT score of 18.1 (SD 7.45). Frequent exacerbators No difference in baseline CAT scores was seen between patients with or without potentially confounding comorbidities (congestive heart failure, renal failure, obesity or sleep disordered breathing, Table 2 ), confirming previous work that CAT scores appear unaffected by low levels of comorbidity (18) .
Use of CAT at exacerbation
The CAT was completed at 152 treated exacerbations by 75 patients. The median interval from diary card exacerbation onset to the day of treatment was 2 days (IQR 1-4). Relationship between CAT score and systemic inflammatory markers at exacerbation CAT scores at exacerbation were significantly related to concurrent levels of systemic inflammatory markers. At exacerbation, serum CRP was measured on the same day as a CAT was completed in 114 exacerbations and plasma fibrinogen in 111 exacerbations. After log 10 transformation, both inflammatory markers were significantly related to the CAT score recorded at exacerbation, and with allowance for repeated measures in the same patient, The CAT is a validated health status questionnaire that is free to use and can be administered without prior permission for research purposes and by individual practitioners (http://www.catestonline.org). Previous studies have shown that the instrument can be successfully administered in both primary (18) and secondary care settings (11) , and is responsive to a course of pulmonary rehabilitation and able to distinguish different levels of response (11) . Additionally, CAT scores exhibit little variability across countries; they are not influenced by age or sex but reflect disease severity in the stable state as determined by
Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric staging, MRC dyspnea score, SGRQ and clinician-judged severity (10, 18).
Our study complements this existing work by demonstrating that the CAT can be used as a score of the multi-dimensional nature of COPD exacerbation severity. At present the assessment of symptom severity at exacerbation and during recovery is subjective in nature, with no established scoring system in clinical practice. Exacerbation therapy is currently determined by a subjective physician assessment of exacerbation severity and so an objective tool to determine exacerbation severity will fulfill an important unmet need. This has particular relevance as patients are increasingly seen by healthcare professionals in the community, often within their own homes, without the benefit of objective measures of exacerbation severity such as accurate spirometry or systemic inflammatory markers. PEFR is a cheap, reliable and easy way for patients to assess lung function on a daily basis. We have shown in previous studies that PEFR decreases to a small extent but significantly at exacerbation onset and can be a useful tool to indicate exacerbation recovery in population studies. However the changes are not large enough to use PEFR at an individual level for exacerbation detection and monitoring (9) .
An objective, validated exacerbation severity score is also required for use in clinical trials.
Treatments to prevent exacerbations may also reduce exacerbation severity in addition to exacerbation frequency but at present tools to determine efficacy of this are limited and only exacerbation rates are usually recorded in clinical studies (19, 20) . Most clinical trials to date have used therapy and hospitalization rates to assess exacerbation severity and thus an objective symptom severity score will enable the ability of novel interventions to reduce exacerbation severity to be assessed and compared across studies (21) . Therapies involving either exacerbation prevention or management of the acute exacerbations may reduce exacerbation CAT scores or the time taken for scores to recover to baseline. Further evaluation of the CAT in clinical trials is now required.
The CAT provides an objective quantification of the impact of symptoms that is acceptable to patients and can be easily completed at exacerbation and during recovery. We have previously shown that systemic inflammation, as measured by plasma fibrinogen and serum When measured in the stable state CAT scores are highly correlated to concurrent SGRQ measurements (10) . However, this study has shown a divergence between the behavior of the CAT and SGRQ during exacerbation recovery. Following a study of exacerbations of chronic bronchitis, whilst an early improvement is seen in SGRQ scores when measured 4
weeks after an index event, improvements can also slowly continue for several months (25) .
In this study we found that CAT scores have returned to baseline levels more rapidly. This may be a result of the daily use of the instrument in this study and the response system in the CAT, which is based on categories of difference between two extreme statements about the same COPD impact. In contrast, the SGRQ has predominantly dichotomous yes/no responses and is administered at intervals. Thus, although we have demonstrated that the CAT can This study has also added to previous data examining the use of the CAT in the baseline stable state by examining the relationship between baseline CAT scores and exacerbation frequency. Patients with a history of frequent exacerbations have worse quality of life (7), increased risk of hospitalization (26) and greater mortality (8) . Frequent exacerbators also exhibit faster decline in lung function (4) and may have worse functional status, as measured by time outdoors (16) . In this study we have shown that baseline CAT scores relate to exacerbation frequency. When used in the stable state, scores were significantly elevated in frequent exacerbators, defined by two or more exacerbations per year, compared to infrequent exacerbators. Also, baseline CAT scores were weakly but significantly related to concurrent fibrinogen levels. We have previously shown that plasma fibrinogen levels are elevated in stable patients with COPD (23) and that increased systemic inflammation, as measured by fibrinogen, in stable COPD patients over time is directly linked to disease progression, as defined by lung function decline (27) . Further work is required to explore whether CAT scores may potentially be a useful marker of disease progression over time in COPD.
Since our results indicate that CAT scores may reflect levels of systemic inflammatory markers, albeit weakly, this finding may have particular relevance in clinical trials of antiinflammatory therapeutic agents in COPD. The effects of anti-inflammatory therapies are difficult to assess as changes in FEV 1 tend to be small (28) and exacerbation frequency as an outcome has to be assessed over at least a 12 month period. Further study is now required of CAT scores during anti-inflammatory interventions in COPD. We have shown that the CAT is a potentially useful, widely applicable tool which can aid assessment of exacerbation severity. The CAT can be easily and rapidly completed in many healthcare settings and could potentially be integrated into care bundles of COPD patients without additional cost. Patient recognition of exacerbation symptoms and prompt treatment improves exacerbation recovery and reduces the risk of hospitalization in COPD patients (31) . Further evaluation is now required of the CAT within exacerbation management strategies to assess utility of the tool within clinical practice.
In conclusion, the CAT provides a reliable score of exacerbation severity. CAT scores increase at exacerbation and reflect exacerbation severity as determined by lung function and exacerbation length. A weak relationship was also found between systemic inflammatory markers and CAT scores at exacerbation. Thus, the CAT is a valuable instrument to enhance and standardize COPD exacerbation assessment. Incorporating this questionnaire into assessment strategies may aid health care professionals to determine the severity of This may be a due to the absence of a specific question assessing sputum purulence in the CAT.
Peak CAT scores
CAT scores rose further following exacerbation onset to reach a maximum, peak CAT score.
CAT scores in the recovery subgroup increased from a mean baseline score of 18.3 (SD 7.5) to a mean peak score of 26.5 (SD 7.1; p<0.001, Figure E2 ).
Repeatability during exacerbations
Of the 75 patients included in the main exacerbation analysis, 38 underwent at least one (increase for two consecutive days in respiratory symptoms, with at least one major symptom (dyspnea, sputum purulence or sputum volume) plus either another major or a minor symptom (wheeze, cold, sore throat, and cough)). This phenomenon of patients experiencing sporadic increases in respiratory symptoms following the end of an exacerbation is also the reason for the slight elevation of symptom counts above baseline at 12 days (recovery time).
The last day of recorded worsening symptoms before two consecutive symptom-free days defined the end of the exacerbation. 
